Skip to main content
HLB Life Science CO.,LTD. logo

HLB Life Science CO.,LTD. — Investor Relations & Filings

Ticker · 067630 ISIN · KR7067630004 LEI · 9884006PTFB20S9PS149 KO Manufacturing
Open in API
Filings indexed 396 across all filing types
Latest filing 2020-02-26 Proxy Solicitation & In…
Country KR South Korea
Listing KO 067630

About HLB Life Science CO.,LTD.

https://www.hlb-lsmc.com/

HLB Life Science is a specialized pharmaceutical and biotechnology firm focused on the development of innovative anti-cancer medications and the manufacturing of medical devices. The company's research and development efforts center on targeted therapies and cell therapies for oncology. In parallel, it develops, manufactures, and distributes in vitro diagnostic (IVD) medical devices and quasi-drugs. The company's portfolio also includes the clinical development of anti-cancer drugs for animals, aiming to provide comprehensive solutions across human and animal health.

Recent filings

Filing Released Lang Actions
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Proxy Solicitation & Information Statement' (PSI) for HLB Life Science Co., Ltd.'s 22nd Annual General Meeting. It contains details about the meeting date, location, agenda items (such as approval of financial statements), and information regarding the solicitation of voting rights (proxy). It is not an Annual Report (10-K) or an Earnings Release (ER), but rather a formal document sent to shareholders to request their votes for the upcoming meeting.
2020-02-26 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 95% confidence The document is a regulatory filing from a Korean company (HLB Life Science) announcing a significant change in financial results (revenue or profit/loss structure exceeding 30%). This is a standard disclosure requirement in the Korean stock market (DART system) for preliminary earnings results. Since it provides key financial highlights and performance metrics rather than a full annual report or a conference call transcript, it falls under the 'Earnings Release' category. FY 2019
2020-02-18 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the closure of the shareholder register for the purpose of determining shareholders eligible to vote at the 22nd Annual General Meeting. It does not contain the full report or proxy materials, but rather serves as a formal notice of a corporate action. Given it is a regulatory announcement that does not fit into specific categories like dividend or share issuance, it is classified as a general regulatory filing.
2019-12-13 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form used in South Korea for reporting insider trading activities by company directors and executives. Based on the provided filing categories, this document falls under 'Director's Dealing' (DIRS), which covers personal share transactions by company directors and executives.
2019-11-18 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea (often referred to as a 5% report). It details changes in share ownership by a major shareholder (HLB Co., Ltd.) and related parties in HLB Life Science Co., Ltd. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks significant ownership thresholds and changes.
2019-11-18 Korean
분기보고서 (2019.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the period 2019-01-01 to 2019-09-30, filed by HLB Life Science Co., Ltd. It contains detailed financial information, business descriptions, and management disclosures required for a quarterly filing. According to the provided definitions, a comprehensive financial report for a period shorter than a full fiscal year is classified as an Interim / Quarterly Report (IR). 9M 2019
2019-11-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.